Evidence map›Paper›PMID 42783069›Full record

ReviewJournal of cardiovascular development and disease2026

Endocrine-Disrupting Chemicals and Hypertension: Mechanisms and Clinical Implications.

Müge Keskin, Gökhan Rıza Baykal, Arzu Or Koca, İlhan Yetkin, Mustafa Cesur

Abstract readReview
In one paragraph

Review in Journal of cardiovascular development and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Müge KeskinDepartment of Endocrinology and Metabolism, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, 06200 Ankara, Türkiye.
Gökhan Rıza BaykalDepartment of Endocrinology and Metabolism, Mardin Training and Research Hospital, 47420 Mardin, Türkiye.ORCID 0000-0002-6601-7791
Arzu Or KocaDepartment of Endocrinology and Metabolism, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, 06200 Ankara, Türkiye.
İlhan YetkinDepartment of Endocrinology and Metabolic Diseases, Faculty of Medicine Hospital, Gazi University, 06500 Ankara, Türkiye.
Mustafa CesurDepartment of Endocrinology and Metabolism, Ankara Güven Hospital, 06540 Ankara, Türkiye.ORCID 0000-0002-1029-2604

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypertension remains one of the leading causes of global morbidity and mortality and is the leading modifiable risk factor for cardiovascular disease worldwide. The inability of conventional risk factors alone to fully explain the global prevalence of hypertension, together with accumulating evidence implicating endocrine-disrupting chemicals (EDCs) in the pathogenesis of hypertension, has led to growing scientific interest in this field over recent years. EDCs are exogenous environmental chemicals capable of disrupting hormone synthesis, transport, metabolism, and signaling pathways, thereby adversely affecting vascular and metabolic homeostasis. In particular, per- and polyfluoroalkyl substances (PFASs), bisphenol A, phthalates, PCBs, heavy metals, and pesticides have been associated with hypertension and may influence blood pressure regulation through multiple interconnected mechanisms, including oxidative stress, endothelial dysfunction, inflammation, epigenetic modifications, and activation of the renin-angiotensin-aldosterone system. Moreover, prenatal exposure to EDCs has been associated with hypertensive disorders of pregnancy, including gestational hypertension and preeclampsia, with potential implications for long-term maternal cardiovascular health. This review provides a comprehensive overview of the experimental and epidemiological evidence linking endocrine-disrupting chemicals to hypertension, with particular emphasis on the underlying molecular mechanisms, emerging clinical evidence, and future research directions.

Indexed as

bisphenol Aendocrine-disrupting chemicalsendothelial dysfunctionhypertensionoxidative stressPFASpreeclampsia

Identifiers

PMID42783069
PMCPMC13607198

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.